A compound of formulae (II), (IV), or (V) or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof:
- wherein:
- each of Ra is independently hydrogen, halo, N(R14)2, C1-15 alkyl, C2-15 alkenyl, C2-15 alkynyl, phenyl, heteroaryl being a monocyclic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N, cycloalkyl containing 3 to 6 carbon atoms, or heterocyclyl containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N, wherein said alkyl, cycloalkyl, heterocyclyl, phenyl, and heteroaryl are optionally substituted with one or more substituents selected from halo, C1-15 alkyl, and O—C1-6 alkyl;
- and wherein each of R14, independent from each other, is selected from hydrogen, C1-15 alkyl, and C3-6 cycloalkyl;
- each of U is N;
- each of R′ and R′″, independently from each other and at each occurrence, are halo, C1-6 alkyl, C2-6 alkenyl, CF3, CN, OR21, N(R21)2, —OC(R21)2O—, —OC(R21)2C(R21)2O—, SO2R22, or SO2N(R21)2, phenyl, heteroaryl being a monocyclic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing 1-3 heteroatoms independently selected from O or N, cycloalkyl containing 3 to 6 carbon atoms, or heterocyclyl containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N, wherein said alkyl, alkenyl, cycloalkyl, phenyl, heterocyclyl, and heteroaryl group is optionally substituted with one or more substituents selected from alkyl, N(R21)2, CON(R21)2, and CN;
- wherein each of R21 and R22 are independently hydrogen, C1-5 alkyl, CF3, phenyl, or heterocyclyl containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N, wherein said alkyl, heterocyclyl, and phenyl substituents are optionally substituted with halo or heterocyclyl containing 3 to 12 carbon atoms and 1 or 2 heteroatoms independently selected from O or N;
- and wherein when W is a nitrogen, R′ may be attached to one carbon atom and the nitrogen atom of the phenyl group thereby forming an imidazo[1,2-a]pyridine ring system;
- each dotted line denotes a bond or an absence of a bond with the proviso that the cycle is aromatic;
- n is an integer in the range from 0 to 4;
- R1′ and R2′, independently from each other and at each occurrence, are selected from the group consisting of hydrogen and C1-4 alkyl;
- each of R3 and R3′ is hydrogen
- each of Rb and Rb′, independent from each other and at each occurrence, are hydrogen or methyl;
- each of R7 is independently hydrogen or methyl;
- each of k is an integer in the range from 4 to 5;
- each of W is, independently and at each occurrence, C-halo, C—R24, or N;
- wherein R24 is hydrogen or an C1-10 alkyl which is optionally substituted by a halogen atom or a phenyl;
- each of E is independently CH2, CH-halo, or NR25, wherein R25 is hydrogen or C1-10 alkyl which is optionally substituted by a halogen atom, or a phenyl;
- each of B is, independently and at each occurrence, C-halo, C—R26, or N, wherein R26 is hydrogen or C1-10 alkyl which is optionally substituted by a halogen atom, or a phenyl;
- each of j′ is an integer in the range from 0 to 3;
- each of R10 is independently hydrogen, halo, C1-6 alkyl, C2-6 alkenyl, C3-6 cycloalkyl, or N(R27)2, wherein R27 is independently hydrogen or an C1-10 alkyl which is optionally substituted by a phenyl.